Core Insights - Lexaria Bioscience Corp. has been granted 5 new patents, enhancing its intellectual property portfolio in drug delivery technologies, particularly in diabetes treatment using GLP-1 drugs [1][2][4] Patent Developments - In Patent Family 21, Lexaria received 2 new patents for hypertension treatment in Japan, issued on February 20, 2026, with a term ending on April 25, 2043. This adds to the existing 3 US and 1 European patents in the same family [2] - In Patent Family 24, Lexaria obtained 1 new patent for epilepsy treatment in Australia, issued on February 12, 2026, with a term ending on February 20, 2044. This complements the existing 6 US, 1 European Union, and 4 Australian patents in this family [3] - In Patent Family 27, Lexaria secured 2 new patents for diabetes treatment in Australia, issued on February 12, 2026, with a term ending on December 3, 2044. This follows the 2 granted US patents in this family [4] Research and Development Focus - Lexaria's ongoing R&D projects aim to advance commercial relationships and establish valuable intellectual property across various jurisdictions. The company anticipates receiving additional patent awards in the future [5] Technology Overview - DehydraTECH™ is Lexaria's patented drug delivery formulation technology that enhances the absorption of drugs through oral delivery, aiming to improve bio-absorption and reduce side effects. The company holds a robust portfolio with 65 patents granted and more pending worldwide [6]

Core Insights - Lexaria Bioscience Corp. is focusing on developing oral GLP-1 drug delivery systems in response to patient preferences for safer and better-tolerated options compared to injected alternatives [2][6][16] Industry Overview - The GLP-1 drug market is experiencing significant growth, with Eli Lilly's tirzepatide projected to be the top-selling drug in 2026, generating approximately $45 billion in revenue, while Novo Nordisk's semaglutide is expected to generate nearly $40 billion [3] - Analysts have raised revenue forecasts for the GLP-1 market, with projections of $139 billion by 2030 from TD Cowen and $180 billion by 2035 from Roots Analysis [3] Patient Experience and Market Needs - A large percentage of patients using GLP-1 drugs experience gastrointestinal side effects, with 74% of injected semaglutide users and 80% of oral semaglutide users reporting such issues [4] - A study indicated that 46.5% of patients with type 2 diabetes and 64.8% without it discontinued GLP-1 drug use within one year, highlighting the need for improved patient experiences [5] Strategic Developments - Lexaria is enhancing its DehydraTECH GLP-1 platform to improve oral delivery and reduce side effects, aiming to establish partnerships with leading pharmaceutical companies [2][17] - The company is in early-stage discussions with several multinational pharmaceutical firms to leverage its patented technology in the GLP-1 market [17] Market Potential - The oral GLP-1 market is anticipated to grow significantly, with forecasts suggesting it could represent a $40 billion to $45 billion annual market within four years [15] - Novo Nordisk's oral GLP-1 tablets are expected to capture over 33% of the GLP-1 market by 2030, up from less than 5% in 2025 [14] Competitive Landscape - Pfizer's orally-delivered GLP-1 candidate, danuglipron, was discontinued due to safety concerns, indicating the challenges in developing new oral alternatives [10] - Eli Lilly is developing orforglipron, which has shown promising results in weight loss studies but also higher rates of adverse side effects compared to semaglutide [13][14]

S-1/A 1 lxrp_s1a.htm FORM S-1/A As filed with the Securities and Exchange Commission on December 5, 2025 Registration No. 333-290862 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to Form S-1 UNDER THE SECURITIES ACT OF 1933 LEXARIA BIOSCIENCE CORP. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or Nevada 2000 20-2000871 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) ...

Core Insights - Lexaria Bioscience Corp. has engaged a global life science business development advisory firm to enhance its business development activities and identify collaborative opportunities in the pharmaceutical and biotechnology sectors [3][4][6] - The company has been awarded four new patents, expanding its intellectual property portfolio and supporting its strategic R&D programs in various therapeutic areas [9][10] Business Development - Lexaria has validated its DehydraTECH technology for applications in diabetes control, weight loss, hypertension, seizure disorders, anti-viral treatments, and hormone replacement [2] - The recent equity financing raised $4.0 million, enabling Lexaria to expand its strategic outreach and R&D activities into 2026 [4][7] - The engagement of the advisory firm is expected to facilitate new outreach activities and strengthen business connections within the pharmaceutical industry [3][6] Research and Development - Lexaria's R&D programs are designed to evolve alongside its business development efforts, with a focus on building strategic connections in the pharmaceutical and biotechnology sectors [5][6] - The company anticipates results from a Phase 1b Australian study in the GLP-1 sector, which is expected to demonstrate patient safety and efficacy with DehydraTECH processing [8] - The newly awarded patents cover therapeutic applications in diabetes, hypertension, seizure disorders, and antiviral treatments, enhancing the company's R&D capabilities [9][10]

Core Insights - Several small-cap stocks experienced significant gains in after-hours trading due to corporate updates, clinical developments, and strategic shifts Company Summaries MEDIROM Healthcare Technologies Inc. (MRM) - Shares surged 282.8% to $5.55 after announcing plans to double the installation of its biometric authentication device "Orb" to 200 stores in collaboration with "World" [2] - Closed at $1.45 during regular trading, down 7.05%, with a trading volume of over 31.5 million shares [3] - The stock has a 52-week range of $0.34 to $5.30, highlighting the scale of its overnight move [3] Lexaria Bioscience Corp. (LEXX) - Shares rose 45.75% to $2.23 following renewed interest in its DehydraTECH drug delivery platform, which enhances GLP-1 drug delivery [4] - Closed at $1.53, up 7.75%, with a volume exceeding 7.5 million shares [5] - The stock's 52-week range is $0.775 to $3.392, with Thursday's close near the midpoint [5] Safety Shot, Inc. (SHOT) - Shares increased 12% to $0.28 after announcing a partnership with Monarq Asset Management to manage its BONK Holdings Treasury [6] - Closed at $0.25, down 9.06%, with a trading volume of over 15.4 million shares [7] - The stock has a 52-week range of $0.23 to $1.35, with the after-hours price near the lower end [7] Aquestive Therapeutics, Inc. (AQST) - Shares rose 11.41% to $5.86 following favorable regulatory news regarding its oral epinephrine candidate, Anaphylm [8] - Closed at $5.26, down 2.95%, with a volume of over 3.6 million shares [9] - The stock's 52-week range is $2.12 to $6.00, with the after-hours price near the upper end [9] Ovid Therapeutics Inc. (OVID) - Shares increased 4.26% to $1.47 after reaching a 52-week high during regular trading, driven by progress in its neurological pipeline [10] - Closed at $1.41, up 0.71%, with a trading volume of over 2.4 million shares [11] - The stock has a 52-week range of $0.2430 to $1.47, with Thursday's close at the top end of its recent performance band [11]

Core Insights - Lexaria Bioscience Corp. has achieved a significant milestone in its Phase 1b GLP-1 study in Australia, completing the last patent last visit (LPLV) [1][2] - The study involved 126 participants and focused on evaluating various DehydraTECH formulations against a control arm using Rybelsus® [4][6] - Interim results have shown positive outcomes, particularly in safety and tolerability compared to the control arm, with a notable reduction in gastrointestinal adverse events [3] Study Details - The study included 24-25 overweight, obese, pre- or type 2 diabetic patients in each of the five study arms, with a total of 126 participants [4] - All doses were administered orally, with no injections involved, as Lexaria aims to shift the standard of care towards oral delivery [4] - The study arms included proprietary formulations of DehydraTECH-CBD and DehydraTECH-processed semaglutide, with the fifth arm evaluating DehydraTECH-tirzepatide [5][6][7] Future Objectives - Lexaria plans to release the final results of the study in the fourth quarter of 2025 [9] - The company is currently engaged in data analysis and sample processing, with a comprehensive database being developed [2] Technology Overview - DehydraTECH™ is Lexaria's patented drug delivery technology that enhances the bio-absorption of drugs through oral delivery, aiming to reduce side effects and improve efficacy [10] - The company holds a robust intellectual property portfolio with 50 patents granted and additional patents pending worldwide [10]

Core Insights - Lexaria Bioscience Corp. has reported positive interim results from its phase 1b study GLP-1-H24-4, focusing on its DehydraTECH drug delivery platform compared to Rybelsus® [1][2] Group 1: Study Results - After 8 weeks of treatment, DehydraTECH-GLP-1 arms showed a significant reduction in adverse events (AEs) compared to Rybelsus®, with 79.2% of DHT-semaglutide patients experiencing at least one AE versus 100% for Rybelsus® [2][4] - DehydraTECH-semaglutide demonstrated a 36.5% reduction in overall AEs and a 43.5% reduction in gastrointestinal (GI) AEs compared to Rybelsus® [3][4] - The total number of AEs for DHT-semaglutide was 61, while Rybelsus® had 96 AEs, indicating a 63.5% reduction in AEs for DHT-semaglutide relative to the control [2][4] Group 2: Efficacy Metrics - The study is assessing changes in glycated hemoglobin (HbA1c) and body weight as primary efficacy endpoints [7] - After 8 weeks, DHT-semaglutide resulted in an average weight loss of -1.14 kg (-1.23%), while DHT-tirzepatide showed a weight loss of -4.14 kg (-4.23%) [9][10] - HbA1c levels decreased by -0.14% for DHT-semaglutide, with no statistically significant difference compared to Rybelsus® at this interim stage (p=0.069) [11] Group 3: Comparative Analysis - In comparison to Novo Nordisk's® STEP studies, where 88.1% of patients experienced AEs, only 79.2% of patients in the DHT-semaglutide arm experienced AEs, suggesting a potential for improved patient adherence to treatment protocols [5] - The DHT-tirzepatide arm showed a lower proportion of GI-related AEs (22%) compared to injected tirzepatide studies, which reported 40% to 50% GI-related AEs [6] Group 4: Future Outlook - Additional data from the study will be processed and may be released in the coming weeks, with final results expected near the end of 2025 [12][13] - The study is approaching the "last patient last visit" milestone and remains on schedule [13]

Industry Overview - The GLP-1 weight loss and diabetes control sector is currently the fastest growing pharmaceutical sector globally, with revenue expectations exceeding $100 billion annually [2] - Updated projections indicate that the GLP-1 industry could generate over $156 billion in revenue by 2030, with a significant growth of 31% expected in 2025, reaching $70.1 billion [3] Challenges in the GLP-1 Sector - The GLP-1 industry faces significant challenges due to unwanted adverse effects, particularly gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation [4] - Discontinuation rates among GLP-1 users with type 2 diabetes are high, with studies showing that 47% to 64% of users stop their medication within 1 to 2 years, primarily due to gastrointestinal adverse effects [5][6] Company Innovations - Lexaria Bioscience Corp. has developed DehydraTECH technology, which aims to reduce side effects associated with GLP-1 drugs, potentially improving patient retention and industry growth [8][9] - DehydraTECH has shown promise in clinical testing for reducing gastrointestinal adverse effects in the top GLP-1 drugs, including semaglutide, tirzepatide, and liraglutide [10] Strategic Initiatives - Lexaria is pursuing a multi-faceted strategy to attract pharmaceutical companies to adopt its DehydraTECH technology, evidenced by a material transfer agreement with a pharmaceutical company announced in September 2024 [11]

Core Insights - Lexaria Bioscience Corp. has successfully completed a human study comparing oral DehydraTECH-liraglutide to injected Saxenda®-branded liraglutide, with partial results now available [1][8] - The study demonstrated a 22.7% reduction in adverse events (AEs) for oral DehydraTECH-liraglutide compared to Saxenda®, with significant reductions in nausea (67%) and gastrointestinal AEs (31%) [3][4] - Lexaria is seeking a pharmaceutical partner to develop an FDA-registered oral alternative to current injectable GLP-1 drugs, addressing an unmet market need [2][10] Study Details - The study involved 10 overweight volunteers, comparing daily doses of Saxenda® (0.6 mg) and DehydraTECH-liraglutide (45 mg) over a 7-day period [13] - The primary endpoint was the evaluation of safety and tolerability, with secondary objectives including pharmacokinetics and effects on body weight, blood glucose, and insulin levels [16] - Weight loss was observed in 9 out of 10 participants in both study arms, although it was not the primary goal of the study [5] Technology and Market Context - DehydraTECH is a patented drug delivery technology that enhances bio-absorption and reduces side effects, with 48 patents granted and more pending [17] - The study's results suggest that DehydraTECH-liraglutide could provide a viable oral alternative to Saxenda® and other injectable liraglutide products, which generated significant revenue for Novo Nordisk [12] - Lexaria's approach may allow for an expedited FDA regulatory pathway under the 505(b)(2) application, contingent on demonstrating comparable performance to existing injectable versions [6][10]

S-1 1 lxrp_s1.htm FORM S-1 As filed with the U.S. Securities and Exchange Commission on June 3, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 UNDER THE SECURITIES ACT OF 1933 LEXARIA BIOSCIENCE CORP. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) Nevada 2000 20-2000871 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 100-740 McCurdy ...